In addition, Disease Free Interval (DFI) analysis demonstrated that PDK1 was a high-risk factor for patients with PCPG, ACC, PAAD and CESC, but a low-risk factor for patients with DLBC and COADREAD (Fig 6C). Here, PDK1 is linked to pancreatic adenocarcinoma.